DiscoveRx Breaks the Barriers of Conventional Cell-Based Screening With Launch of a Powerful New InCELL Hunter™ Platform
Release date: 6/5/2012
California, USA - June 5th, 2012 - DiscoveRx , a leader in innovative cell based assays for GPCRs, Kinases, NHRs and Proteases today unveiled a break-through technology called InCELL Hunter™. This platform marks a significant step forward as compared to other cell-based assay platforms currently available for Kinases, Epigenetics and other enzyme targets. This novel technology allows researchers to evaluate compound binding to a target of interest directly in a cellular environment.
"The simplicity of the assay coupled with the accuracy, applicability to a broad range of target classes makes InCELL Hunter an exciting platform for many emerging targets or those for which traditional cell-based assays have been a struggle ," said Dr. Pyare Khanna, President and Chief Executive Officer, DiscoveRx Corporation.
By delivering all the advantages of well-recognized PathHunter® cell-based chemiluminescent assay platform, InCELL Hunter technology enables users to screen for compound binding in live cells against a wide number of drug targets including serine-threonine kinases, bromo-domains, methyl transferases and other emerging targets. “The powerful capabilities and cost effectiveness of this new platform are perfectly aligned with the needs of drug discovery customers. DiscoveRx is committed to be a leading provider of drug discovery solutions for key target classes such as GPCRs, Kinases, NHRs and other emerging target classes involved in Epigenetics” added Dr. Khanna.
A convenient departure from standard thermal shift assays or other mass spec analysis, InCELL Hunter uses a novel method of measuring compound binding to a target of interest in cells. The assay is a simple one-step process where the signal is read on a standard chemiluminescent plate reader enabling both smaller screens as well as full deck high throughput screens.
DiscoveRx will soon release kinase and epigenetic assays based on InCELL Hunter technology. The company is also soliciting market feedback and opportunities to collaborate using this technology platform for other target classes. Send your requests to firstname.lastname@example.org.
About DiscoveRx Corporation
Founded in 2000, DiscoveRx is a privately held, venture-backed company headquartered in Fremont, California, with additional offices in San Diego, California and Birmingham, England. The Company pioneered the use of β-galactosidase enzyme fragment complementation (EFC) in HitHunter® biochemical and PathHunter® cell-based assays for discovery research. In addition to the EFC platform, DiscoveRx also holds extensive intellectual property for its second core technology, an in vitro binding assay platform called KINOMEscan®. Utilizing these two proprietary platforms, DiscoveRx has developed and commercialized industry leading panels of GPCR, Kinase, and NHR assay solutions for drug discovery research. Many of DiscoveRx’s innovative solutions have been widely adopted in pharmaceutical, academic and biotechnology laboratories worldwide. For more information, visit www.discoverx.com.
Sr. VP Business Development
42501 Albrae Street, Fremont, CA 94538
tel | 510.979.1415 x104